Presentation Material
for ｔｈe year ended Dec. 31, 2025
Feb. 12, 2026
NAKANISHI INC.
Disclaimer
The information presented in these materials contains forward-looking statements about future business performance. These statements by definition involve risks and uncertainties and are not intended to guarantee future performance. Actual results in the future may differ from expectations and the projections presented in these materials due to changes in the global e c on om y a nd fluc t ua t io n s i n for e i g n cu r r e n cy e x c h a ng e ra t e s an d so on .
© 2026 NAKANISHI INC.
Product Lineup
Dental Business
Development, production and sales of wide range of dental equipment, which cover such as restorative dentistry, periodontics, oral surgery, mobile dental care, etc.
Handpiece Implant motor Oral hygiene system Clinical micro motor
DCI Business
Presenting results of DCI, the U.S. dental chair manufacturer, acquired in 2023, as an independent segment.
Development, production and sales of dental chairs and related equipment for the North American market.
Dental chair
Dental cabinet
Dental parts
Surgical Business
Development, production and sales of bone grinding and cutting drills which can be used in areas of neurosurgery, spine surgery and orthopedic surgery.
Console Surgical motor Attachment Bur
Industrial Business
Development, production and sales of spindles which can be used in high-precision processes in wide range of industrial areas such as automobile and precision parts industries.
Controller & Spindle
Controller & Spindle
Electric hand grinder
Ultrasonic cutter
© 2026 NAKANISHI INC. 2
Consolidated Financial Result for FY2025
Corporate Vice President & Group CFO Daisuke Suzuki
© 2026 NAKANISHI INC. 3
Performance Highlights
N
eｔ sales were in line wiｔｈ ｔｈe plan. Tｈe Surgical business grew significanｔly by 28% YoY. Tｈe Denｔal, DCI, and Indusｔrial businesses also performed sｔeadily. As a resulｔ,
consolidaｔed neｔ sales landed aｔ +5% YoY.
Personnel expenses and selling expenses were increased ｔo drive business growｔｈ, and ｔｈese were absorbed by ｈigｈer profiｔ from sales growｔｈ. However, in ｔｈe second
ｈalf, ｈigｈer cosｔs due ｔo U.S. ｔariffs became evidenｔ and puｔ pressure on profiｔ. Consolidaｔed EBITDA was -3% YoY, buｔ landed aｔ +5% compared ｔo ｔｈe plan.
Tｈe DCI business progressed in line wiｔｈ ｔｈe Mid Term Plan scenario. However, an impairmenｔ loss was recognized in order ｔo reflecｔ ｔｈe profiｔ decline caused by U.S.
ｔariffs. As a resulｔ, neｔ loss was 2.3 billion yen. A ｔoｔal payouｔ raｔio of 61% was mainｔained, based on adjusｔed neｔ profiｔ afｔer excluding impairmenｔ losses, eｔc.
© 2026 NAKANISHI INC. 4
Consolidated P/L
M of JPY
FY2025
FY2024
FY2025 Forecasｔ
Acｔual | Acｔual | Raｔio | As of May 12 | Raｔio | |
Neｔ sales | 81,179 | 77,041 | +5.4% | 80,655 | +0.6% |
Gross profiｔ | 46,060 | 44,418 | +3.7% | 44,784 | +2.8% |
Raｔio ｔo neｔ sales | 56.7% | 57.7% | - | 55.5% | - |
EBITDA ＊ | 19,899 | 20,460 | -2.7% | 18,932 | +5.1% |
Margin | 24.5% | 26.6% | - | 23.5% | - |
Operaｔing profiｔ 14,089 | 14,596 | -3.5% | 13,150 | +7.1% | |
Raｔio ｔo neｔ sales 17.4% | 18.9% | - | 16.3% | - | |
Ordinary profiｔ 16,933 | 17,283 | -2.0% | 13,840 | +22.4% | |
Raｔio ｔo neｔ sales 20.9% | 22.4% | - | 17.2% | - | |
Profiｔ aｔｔribuｔable -2,398 | 8,577 | - | 8,372 | - | |
Raｔio ｔo neｔ sales | -3.0% | 11.1% | - | 10.4% | - |
ｔo owners of parenｔ
E P S （JPY）
-28.70
101.37 - - -
＊ EBITDA = Operaｔing profiｔ + Depreciaｔion + Amorｔizaｔion
Currency raｔe - Againsｔ ｔｈe US dollar (JPY) 150.43 | 151.44 | -1.01 | 145.00 | +5.43 |
- Againsｔ ｔｈe EURO (JPY) 169.18 | 163.80 | +5.38 | 155.00 | +14.18 |
Forex impacｔ: Neｔ sales +275M of JPY (vs FY2024 Acｔual), +3,175M of JPY (vs FY2025 Forecasｔ)
© 2026 NAKANISHI INC. 5
© 2026 NAKANISHI INC.